Title : Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.

Pub. Date : 2019 Apr

PMID : 30393950






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSION: When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycaemia. Insulin Glargine insulin Homo sapiens